Impact of Colchicine and Low-dose Naltrexone on COVID-19
Status:
Enrolling by invitation
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the impact of two medications-colchicine and low-dose
naltrexone (LDN)-relative to standard of care (SOC) on COVID-19 disease progression to
severe/critical illness and/or intubation in patients hospitalized with moderate COVID-19. As
researchers have learned, COVID-19's clinical course suggests that the hyperinflammatory
response seen in severe/critical cases is involved in the pathogenesis of associated adverse
sequelae such as acute respiratory distress syndrome (ARDS), thromboembolic disease, and
acute cardiac injury. Given colchicine has demonstrated clinical utility in inflammatory
syndromes within these systems (e.g. endothelial/vascular/myocardial), and LDN acts both to
boost the immune system, and limit an excessive response; they may prove useful in minimizing
the risk of disease progression and associated adverse sequelae.